ALGS
ALGS clinical trials: Aligos Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Aligos Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 16
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALGS on the catalyst calendar · ALGS registry changes
- Primary completion Aug 6, 2027Sponsor estimatePhase 1NCT07943377Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism...Aligos Therapeutics · Healthy ParticipantsNot yet recruitingALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT06963710A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and...Aligos Therapeutics · Chronic Hepatitis B InfectionActive, not recruitingALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2026ActualPhase 1NCT07342881Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With...Aligos Therapeutics · Chronic Hepatitis B InfectionCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2026ActualPhase 1NCT07342868Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With...Aligos Therapeutics · Chronic Hepatitis B InfectionsCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2025ActualPhase 1NCT06698549A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy...Aligos Therapeutics · COVID 19CompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2025ActualPhase 1NCT06568861A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy...Aligos Therapeutics · COVID-19CompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2025ActualPhase 1NCT04536337A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in...Aligos Therapeutics · Chronic Hepatitis BCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2025ActualPhase 1NCT06959888A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 FormulationsAligos Therapeutics · Healthy Volunteer StudyCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2024ActualPhase 1NCT05840952A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug...Aligos Therapeutics · COVID-19CompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2024ActualPhase 2NCT06342947ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)Aligos Therapeutics · NASHCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2023ActualPhase 1NCT06191991A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)Aligos Therapeutics · Healthy VolunteersCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2025Sponsor estimatePhase 1NCT06672900A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and...Aligos Therapeutics · Healthy VolunteerActive, not recruitingALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2023ActualPhase 1NCT05561530A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers...Aligos Therapeutics · Chronic Hepatitis BTerminatedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2023ActualPhase 1NCT05090111A Study of ALG-055009 in Healthy Volunteers and Subjects With HyperlipidemiaAligos Therapeutics · NASH - Nonalcoholic SteatohepatitisCompletedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2022ActualPhase 1NCT05001022A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy...Aligos Therapeutics · Chronic Hepatitis BTerminatedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 8, 2022ActualPhase 1NCT04485663A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in...Aligos Therapeutics · Chronic Hepatitis BTerminatedALGSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner